PRME Stock Rises 11.8% on Collaboration With Bristol Myers

Shares of Prime Medicine, Inc. (PRME) were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb (BMY) . The collaboration is aimed at developing reagents for the next generation of ex vivo T-cell therapies. Year to date, PRME's shares have lost 56.3% compared with the industry's decline of 1.2%. Image Source: Zacks Investment Research Terms of PRME's Deal With BMY Prime Medicine is deploying its proprietary gene editing techno ...